\-\ Texto\\:\\ \ \(0\)\
\-\ alpha\\-fetoprotein\\ 0\\.6\\ ng\\/dl\\ \\(0\\.0\\-15\\.0\\ ng\\/dl\\)\ \(0\)\
\-\ the\\ patient\\ underwent\\ surgical\\ resection\\ of\\ hepatic\\ segments\\ 5\\ and\\ 6\\ with\\ pathology\\-confirmed\\ hepatocellular\\ carcinoma\\ measuring\\ 6cm\\.\\ \\ no\\ lymph\\-vascular\\ invasion\\.\\ \\ the\\ surgical\\ margins\\ were\\ negative\\ for\\ tumor\\.\\ \\ underlying\\ liver\\ changes\\ consistent\\ with\\ chronic\\ hepatitis\\.\ \(0\)\
\-\ three\\ phase\\ intravenous\\ contrast\\-enhanced\\ ct\\ of\\ the\\ liver\\ demonstrates\\ a\\ subtle\\ hypodense\\ mass\\ in\\ segment\\ 5\\.\\ \\ arterial\\ phase\\ images\\ demonstrate\\ contrast\\ enhancement\\ within\\ the\\ lesion\\ with\\ a\\ serpentine\\ appearance\\.\\ \\ delayed\\ images\\ demonstrate\\ diffuse\\,\\ heterogeneous\\ enhancement\\ of\\ the\\ mass\\.\ \(0\)\
\-\ hepatocellular\\ carcinoma\ \(28\)\
\-\ metastatic\\ disease\ \(243\)\
\-\ hepatocellular\\ carcinoma\ \(28\)\
\-\ 47\\ y\\/o\\ male\\ with\\ colon\\ cancer\\ found\\ to\\ have\\ liver\\ lesion\\ on\\ metestatic\\ screening\\ ct\\.\ \(0\)\
\-\ Keywords\\ by\\ value\\:\\ \ \(0\)\
\-\ hepatocellular\\:\\ 0\\.3784315984062961\ \(0\)\
\-\ liver\\:\\ 0\\.25393443846970115\ \(0\)\
\-\ carcinoma\\:\\ 0\\.22018255561213637\ \(0\)\
\-\ phase\\:\\ 0\\.20998912648650184\ \(0\)\
\-\ metestatic\\:\\ 0\\.18750402905378746\ \(0\)\
\-\ serpentine\\:\\ 0\\.1436906553415063\ \(0\)\
\-\ enhancement\\:\\ 0\\.1412491056576454\ \(0\)\
\-\ 6cm\\:\\ 0\\.14024168151747715\ \(0\)\
\-\ demonstrate\\:\\ 0\\.1275776856812858\ \(0\)\
\-\ hepatitis\\:\\ 0\\.12614386613543202\ \(0\)\
\-\ segments\\:\\ 0\\.12454980207331114\ \(0\)\
\-\ the\\:\\ 0\\.12241646585636905\ \(0\)\
\-\ surgical\\:\\ 0\\.11927336552629292\ \(0\)\
\-\ contrast\\:\\ 0\\.11923580983410423\ \(0\)\
\-\ hypodense\\:\\ 0\\.11914402335919302\ \(0\)\
\-\ lesion\\:\\ 0\\.11765116658747359\ \(0\)\
\-\ images\\:\\ 0\\.11351475209090761\ \(0\)\
\-\ 47\\:\\ 0\\.1125124545354118\ \(0\)\
\-\ intravenous\\:\\ 0\\.11186386204104494\ \(0\)\
\-\ invasion\\:\\ 0\\.10944898998257398\ \(0\)\
\-\ subtle\\:\\ 0\\.1057825642295376\ \(0\)\
\-\ margins\\:\\ 0\\.10468727199806667\ \(0\)\
\-\ segment\\:\\ 0\\.1013062067429436\ \(0\)\
\-\ arterial\\:\\ 0\\.10104704672440926\ \(0\)\
\-\ underlying\\:\\ 0\\.10016381326734189\ \(0\)\
\-\ screening\\:\\ 0\\.0996749281017562\ \(0\)\
\-\ hepatic\\:\\ 0\\.09771286981773832\ \(0\)\
\-\ with\\:\\ 0\\.09610554989758426\ \(0\)\
\-\ delayed\\:\\ 0\\.09601662018892584\ \(0\)\
\-\ measuring\\:\\ 0\\.09492349707169415\ \(0\)\
\-\ mass\\:\\ 0\\.09373700390653321\ \(0\)\
\-\ ct\\:\\ 0\\.09342683642978776\ \(0\)\
\-\ colon\\:\\ 0\\.09342654388031987\ \(0\)\
\-\ heterogeneous\\:\\ 0\\.08880824157539721\ \(0\)\
\-\ underwent\\:\\ 0\\.08452497952536163\ \(0\)\
\-\ three\\:\\ 0\\.0823664924672612\ \(0\)\
\-\ cancer\\:\\ 0\\.0817275339620581\ \(0\)\
\-\ found\\:\\ 0\\.07939313241362712\ \(0\)\
\-\ resection\\:\\ 0\\.07865292961111968\ \(0\)\
\-\ diffuse\\:\\ 0\\.0769487070426248\ \(0\)\
\-\ negative\\:\\ 0\\.07596334294524475\ \(0\)\
\-\ changes\\:\\ 0\\.07415536057820647\ \(0\)\
\-\ appearance\\:\\ 0\\.0739716701251102\ \(0\)\
\-\ chronic\\:\\ 0\\.07283179967119166\ \(0\)\
\-\ of\\:\\ 0\\.0720361208581407\ \(0\)\
\-\ metastatic\\:\\ 0\\.06729535399720514\ \(0\)\
\-\ consistent\\:\\ 0\\.06653129250722829\ \(0\)\
\-\ tumor\\:\\ 0\\.0641797358668237\ \(0\)\
\-\ were\\:\\ 0\\.06324881394147838\ \(0\)\
\-\ demonstrates\\:\\ 0\\.06164364219961931\ \(0\)\
\-\ have\\:\\ 0\\.06129587393709471\ \(0\)\
\-\ within\\:\\ 0\\.05651229149503582\ \(0\)\
\-\ male\\:\\ 0\\.05463120003354297\ \(0\)\
\-\ disease\\:\\ 0\\.0515055158509592\ \(0\)\
\-\ patient\\:\\ 0\\.03990847172536714\ \(0\)\
\-\ no\\:\\ 0\\.03990096517448482\ \(0\)\
\-\ for\\:\\ 0\\.03718972782599823\ \(0\)\
\-\ on\\:\\ 0\\.03705780455853469\ \(0\)\
\-\ to\\:\\ 0\\.030675006022912402\ \(0\)\
\-\ in\\:\\ 0\\.030524023706797746\ \(0\)\
\-\ and\\:\\ 0\\.02535465698432828\ \(0\)\
